Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib Combination Therapy in Second-line and Above Metastatic Colorectal Cancer
NCT07714447Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of tunlametinib in colorectal cancer (CRC) (3 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 180 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tunlametinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07714447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714447.